SOURCE: The Bedford Report

The Bedford Report

April 28, 2011 08:16 ET

Speculative Biotech Firms Seek Long Term Revenue Drivers

The Bedford Report Provides Analyst Research on BioSante & Exelixis

NEW YORK, NY--(Marketwire - Apr 28, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Exelixis, Inc. (NASDAQ: EXEL). Access to the full company reports can be found at:

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. Earlier this month shares of the company got a boost after it announced that the Food and Drug Administration (FDA) will review an application for a testosterone gel it developed and then licensed to a unit of Teva Pharmaceutical Industries. BioSante will receive milestone payments and royalties upon commercialization.

Exelixis also saw its share price surge this month after reports from Bloomberg surfaced claiming that the Exelixis hired Goldman Sachs to handle potential takeover bids following the company's positive results in a study of its experimental prostate cancer treatment, cabozantinib.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information